Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2–3.
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80–7.
Attwood S, Ell C, Galmiche J, Fiocca R, Hatlebakk J, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41:1162–74.
Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. Cancer. 1996;78:1447–82.
Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol. 2000;18:463–3.
Wang B-Y, Zhang J, Wang J-L, Sun S, Wang Z-H, Wang L-P, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:85.
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–6.
Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265:419–28.
Kuller LH. Do proton pump inhibitors increase the risk of dementia? JAMA Neurol. 2016;73:379–81.
Batchelor R, Gilmartin JF, Kemp W, Hopper I, Liew D. Dementia, cognitive impairment and proton pump inhibitor therapy: a systematic review. J Gastroenterol Hepatol. 2017;32:1426–35.
Kohli S, Griggs JJ, Roscoe JA, Jean-Pierre P, Bole C, Mustian KM, et al. Self-reported cognitive impairment in patients with cancer. J Oncol Pract. 2007;3:54–9.
Savard J, Ganz PA. Subjective or objective measures of cognitive functioning—What’s more important? JAMA Oncol. 2016;2:1263–4.
Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.
Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11:6–15.
Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol. 2007;25:3866.
Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst. 2005;97:448–56.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
Mizyed I, Fass S, Fass R. Gastro-oesophageal reflux disease and psychological comorbidity. Aliment Pharmacol Ther. 2009;29:351–8.
McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009;119:1–8.
Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology. 2004;13:61–6.
Greene-Schloesser D, Robbins ME. Radiation-induced cognitive impairment-from bench to bedside. Neuro-Oncol. 2012;14:iv37–44.
Rosano C, Simonsick EM, Harris TB, Kritchevsky SB, Brach J, Visser M, et al. Association between physical and cognitive function in healthy elderly: the health, aging and body composition study. Neuroepidemiology. 2005;24:8–14.
Deary IJ, Corley J, Gow AJ, Harris SE, Houlihan LM, Marioni RE, et al. Age-associated cognitive decline. Br Med Bull. 2009;92:135–52.
Evans DA, Beckett LA, Albert MS, Hebert LE, Scherr PA, Funkenstein HH, et al. Level of education and change in cognitive function in a community population of older persons. Ann Epidemiol. 1993;3:71–7.
Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, et al. Yoga’s impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2014;32:1040–9.
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol. 1997;15:974–86.
Von Ah D, Tallman EF. Perceived cognitive function in breast cancer survivors: evaluating relationships with objective cognitive performance and other symptoms using the functional assessment of cancer therapy—cognitive function instrument. J Pain Symptom Manag. 2015;49:697–706.
Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG, Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015;7:79.
Park S, Nam JH, Lee H, Chung H, Lee E, Shin J. Beyond uncertainty: negative findings for the association between the use of proton pump inhibitors and risk of dementia. J Gastroenterol Hepatol. 2019.
Hussain S, Singh A, Zameer S, Jamali MC, Baxi H, Rahman SO, et al. No association between proton pump inhibitors use and risk of dementia: evidence from a meta-analysis. J Gastroenterol Hepatol. 2019.
Gray SL, Walker RL, Dublin S, Yu O, Aiello Bowles EJ, Anderson ML, et al. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc. 2018;66:247–53.
Kwa M, Plottel CS, Blaser MJ, Adams S. The intestinal microbiome and estrogen receptor–positive female breast cancer. JNCI J Natl Cancer Inst. 2016;108.
Parrilli G, Iaffaioli RV, Martorano M, Cuomo R, Tafuto S, Zampino MG, et al. Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res. 1989;49:3689–91.
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors. Can Fam Physician. 2017;63:354–64.
Al-Qaisi M, Kahn A, Crowell M, Burdick G, Vela M, Ramirez F. Do recent reports about the adverse effects of proton pump inhibitors change providers’ prescription practice? Dis esophagus. 2018;
Björnsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24:945–54.
Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–56.
Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13:701.
Marlicz W, Koulaouzidis A, Loniewski I, Koulaouzidis G. Letter by Marlicz et al Regarding Article,“Proton Pump Inhibitors Accelerate Endothelial Senescence.”. Circ Res. 2016;119:e31–2.
Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2010;19:573–89.
Badiola N, Alcalde V, Pujol A, Münter L-M, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8:e58837.
Fallahzadeh M, Borhani Haghighi A, Namazi M. Proton pump inhibitors: predisposers to Alzheimer disease? J Clin Pharm Ther. 2010;35:125–6.